Login to Your Account

Allicense 2011

Go Long [Term]: Amgen's M&A Playbook Offers Range of Deals

By Jennifer Boggs

Wednesday, May 4, 2011
SAN FRANCISCO – Burrill & Co. reported last month that the past decade of merger and acquisition (M&A) activity by major pharmaceutical firms has failed to build value, suggesting that the drug development industry might be wasting its time on acquisitions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription